MiRNA-based therapy for Melanoma: Metformin, the widely used drug in the treatment of NIDDM, suppresses the expression of Mcl-1 via up regulation of its target gene , 14/September/2014, 22.07

MiRNA-based therapy for Melanoma: Metformin, the widely used drug in the treatment of NIDDM, suppresses the expression of Mcl-1 via up regulation of its target gene , 14/September/2014, 22.07

MiRNA-based therapy for Melanoma: Metformin, the widely used drug in the treatment of NIDDM, suppresses the expression of Mcl-1 via up regulation of its target gene , 14/September/2014, 22.07 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathanMiRNA-based therapy for Melanoma: Metformin, the widely used drug in the treatment of NIDDM, suppresses the expression of Mcl-1 via up regulation of its target gene , 14/September/2014, 22.07, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: This study suggests that Metformin, by increasing the expression of its target miRNA, it may suppress the expression of Mcl-1.  Thereby, it may inhibit invasion and metastatic property of tumor cells.  Thus, pharmacological formulations encompassing “Metformin or its related analogs” may used to treat Melanoma.